LIFE SAVING DRUGS PROGRAM EXPERT PANEL

SIXTH MEETING: 25-26 June 2020

**AGENDA**

# Standing business

* 1. Welcome & apologies
  2. Declaration of potential or actual Conflict of Interest
  3. Correspondence
  4. Report from the Secretariat

# Reviews of existing LSDP medicines

TRANCHE 1 – review of **final** reports

* 1. imiglucerase (Cerezyme®), velaglucerase (VPRIV®) and taliglucerase (Elelyso®) for treatment of Gaucher disease

TRANCHE 2 – review of **final** reports

* 1. eculizumab (Soliris®) for treatment of Paroxysmal Nocturnal Haemoglobinuria
  2. idursulfase (Elaprase®) for treatment of Mucopolysaccharidosis type II
  3. alglucosidase alfa (Myozyme®) for treatment of Pompe disease

TRANCHE 3 – review of **draft** reports

* 1. laronidase (Aldurazyme®) for treatment of Mucopolysaccharidosis type I
  2. galsulfase (Naglazyme®) for treatment of Mucopolysaccharidosis type VI
  3. nitisinone (Orfadin®) for Hereditary Tyrosinaemia type I

# Applications for new LSDP medicines

# Other business